

Please amend the application as follows:

In the Claims:

For the Examiner's convenience, Applicants present all pending claims with status indicators.

Claim 74. (currently amended) An anti-allergic pharmaceutical composition comprising

- (a) an acarid allergen ~~comprising~~ consisting of
 - ~~i. the allergen encoded by the polynucleotide of SEQ ID NO:1,~~
 - ~~ii. the allergen as shown in SEQ ID NO:2,~~
 - iii. the allergen as shown in SEQ ID NO:3,
 - iv. the allergen as shown in SEQ ID NO:4, and/or
 - v. the allergen as shown in SEQ ID NO:5,
- (b) an antihistamine selected from the group consisting of brompheniramine, cetirizine, fexofenadine, cyproheptadine, dexchlorpheniramine, hydroxyzine, ketotifene, loratidine, mequitazine, oxotomide, mizolastine, ebastine, astemizole, carbinoxamide, alimemazine, buclizine, cyclizine hydrochlorate and doxylamine,
- (c) an inhibitor of histamine synthesis, wherein the inhibitor comprises ~~an~~ inhibitor of histidine decarboxylase, and
- (d) a pharmaceutically acceptable carrier.

Claim 75. (previously presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D. Pteronyssinus*.

Claim 76. (previously presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is *D. Farinae*.

Claim 77. (previously presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is a cystine protease.

Claim 78. (previously presented) The pharmaceutical composition of claim 82, wherein the inhibitor of histidine decarboxylase is tritoqualine.

Claim 79. (currently amended) A method for ~~reducing~~ treating an allergic hypersensitivity reaction comprising administration of the pharmaceutical composition of claim 74 to a subject.

Claim 80. (currently amended) The method of claim 79, wherein ~~reducing~~ the allergic hypersensitivity reaction ~~treats allergic hypersensitivity~~ is reduced in the subject.

Claim 81. (previously presented) The pharmaceutical composition of claim 74, wherein the acarid allergen is present in an amount of 1 to 1500 micrograms or 10 to 150 micrograms.

Claim 82. (previously presented) The pharmaceutical composition of claim 74, wherein the antihistamine is present in an amount of 1 to 2000 milligrams or 5 to 200 milligrams.

Claim 83. (currently amended) The pharmaceutical composition of claim 74, wherein the inhibitor of histamine synthesis is present in an amount of between 1 to 2000 milligrams, 5 to 200 milligrams or 10 to 300 milligrams.

Claims 74-83 are pending.

The changes to the claims are in accord with the Examiner's suggestion in the May 19, 2005 telephone conference. The changes place the case in condition for allowance.

If a telephone interview would be of assistance in advancing prosecution of the present application, Applicants' undersigned attorney invites the Examiner to telephone her at the number provided below.

No fee is deemed necessary in connection with the filing of this Amendment. If any further fee is necessary, the Patent Office is authorized to charge the additional fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Patent Attorneys for Applicants
Mandel & Adriano
55 So. Lake Ave., Suite 710
Pasadena, California 91101
626/395-7801
Customer No: 26,941